NCT06558643View on ClinicalTrials.gov

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 27, 2024

Primary Completion Date

September 3, 2025

Study Completion Date

September 3, 2025

Conditions
Malaria,Falciparum
Interventions
DRUG

MMV371 LAI

Single intra-muscular dose

DRUG

Placebo for MMV371

Single intramuscular dose

Trial Locations (1)

NG11 6JS

Quotient Sciences, Ruddington

All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

collaborator

The Doctors Laboratory Ltd

INDUSTRY

lead

Medicines for Malaria Venture

OTHER

NCT06558643 - Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants | Biotech Hunter | Biotech Hunter